Ann: Chairman's Address to Shareholders , page-2

"We have generated significant interest from pharmaceutical partners in the HA-Irinotecan program and our licensing discussions are currently underway with multiple parties."


In their presentation 2014 key activities is stating potential partnership. I take it that these companies are probably willing to wait for the TOP-LINE data before signing a mind blowing deal :-)


Again they have mentioned potential monetization of Fonda, it would be nice if someone coming from the AGM can tell us what they meant by monetization just to be clear.